Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Adcetris (brentuximab vedotin ADC by Quarter
Adcetris (brentuximab vedotin ADC — lymphoma, via Seagen) — Worldwide operational (constant-currency) YoY (%) (%)
Pfizer Adcetris (brentuximab vedotin ADC: -23.0% in Q2 2026, down 14.0 pts from a year earlier.
Where the Q2 2026 figure comes from
“|| Adcetris (e) | 196 | 255 | (23%) | (23%) | 192 | 248 | (23%) | 4 | 6 | (37%) | (39%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Adcetris (brentuximab vedotin ADC — lymphoma, via Seagen) — Worldwide operational (constant-currency) YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | -23.0% | -14.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | -13.0% | +2.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | -23.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 28, 2025 | -20.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | -9.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | -15.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗ |
Cite this data
StockData. (2026). Pfizer Adcetris (brentuximab vedotin ADC (%), quarterly Q1 2025–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/adcetris-oper-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.